stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) EV/FCF
As of 6 November 2026, Grifols, S.A. (GRFS) trades at a EV/FCF of 20.8×. Over the past ten years it has ranged from −279× (September 2024) to 2,074× (February 2023); the current reading is higher than 23% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 25.2× | (50.74%) |
| FY2024 | 51.2× | — |
| FY2023 | −59.2× | — |
| FY2022 | 1,913× | 7,389.70% |
| FY2022 | 25.5× | 0.83% |
| FY2021 | 25.3× | (25.51%) |
| FY2021 | 34.0× | 1.71% |
| FY2020 | 33.4× | (36.49%) |
| FY2020 | 52.7× | 1.00% |
| FY2019 | 52.1× | 37.00% |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 19.7× | (25.16%) |
| Mar 2026 | 26.4× | 4.50% |
| Dec 2025 | 25.2× | (28.40%) |
| Sep 2025 | 35.2× | (43.49%) |
| 29 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| AMRN Amarin Corporation PLC compare | −1.7× |
| NSRX Nasus Pharma Ltd. compare | 0.4× |
| SNY Sanofi compare | 7.6× |
| GSK GSK PLC Sponsored ADR compare | 14.6× |
| BMY Bristol Myers Squibb Company compare | 16.9× |
| OGN Organon & Co. compare | 18.8× |
| GRFS Grifols, S.A. | 20.8× |
| BIIB Biogen Inc. compare | 25.2× |
| NVO Novo Nordisk A/S compare | 27.7× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement